Nurix Therapeutics (NRIX) Non-Current Assets (2019 - 2026)

Nurix Therapeutics (NRIX) has reported Non-Current Assets for 8 consecutive years, with $79.1 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Non-Current Assets rose 3.72% year-over-year to $79.1 million; the TTM figure through May 2026 stood at $324.0 million (up 37.82% YoY), while the FY2025 annual figure was $81.3 million, up 62.78% from the prior year.
• Non-Current Assets slipped to $79.1 million in Q2 2026 per NRIX's latest filing, from $81.7 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $157.2 million in Q1 2022 and bottomed at $40.2 million in Q3 2023.
• Historically, Non-Current Assets has averaged $76.2 million across 5 years, with a median of $77.6 million in 2025.
• Annual changes were most pronounced in 2022 — Non-Current Assets surged 83.06% — and 2023, when it slumped 61.47%.
• Nurix Therapeutics' Non-Current Assets stood at $98.3 million in 2022, then slumped by 38.87% to $60.1 million in 2023, then retreated by 16.87% to $50.0 million in 2024, then jumped by 62.78% to $81.3 million in 2025, then declined by 2.78% to $79.1 million in 2026.
• Business Quant data shows NRIX's Non-Current Assets at $79.1 million in Q2 2026, $81.7 million in Q1 2026, and $81.3 million in Q4 2025.